ABBOTT LABORATORIES acquired Tendyne Holdings, Inc. for $250M, a transaction completed in September 2015, structured as Acquisition of remaining equity (buyout of stake not already owned).
Tendyne Holdings, Inc. operates in Structural Heart / Medical Devices, is based in United States. Tendyne Holdings is a private medical-device company developing minimally invasive mitral valve replacement therapies; its Bioprosthetic Mitral Valve System is designed to be implanted in a beating heart without open-heart surgery. Abbott acquired the equity it did not already own to broaden its foundation in treatments for mitral valve disease.
Broadens Abbott's leadership in mitral valve disease with a less-invasive valve replacement option.
Advisory firms were not disclosed for this transaction.